The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers - PubMed (original) (raw)

Randomized Controlled Trial

The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers

R De La Garza 2nd et al. Pharmacol Biochem Behav. 2008 Apr.

Abstract

A human laboratory model of intravenous methamphetamine self-administration may facilitate study of putative treatments for methamphetamine addiction. We conducted a double-blind, placebo-controlled, between groups investigation of the acetylcholinesterase (AChE) inhibitor rivastigmine in non-treatment-seeking volunteers who met criteria for methamphetamine abuse or dependence. Safety and subjective effects data derived from days 1-10 of this protocol are described in a separate publication. In this report, we describe self-administration outcomes in participants randomized to treatment with rivastigmine (0 mg, N=7; 1.5 mg, N=6; 3 mg, N=9); data that were collected on days 11-15 of the inpatient protocol. On day 11, participants sampled two infusions of methamphetamine (0 and 30 mg, i.v.). On days 12-15, participants made ten choices each day to receive an infusion of either methamphetamine (3 mg, IV) or saline or a monetary alternative ($0.05-$16). The study design allowed for evaluation of differences in behavior on days in which infusions were performed by the physician (experimenter-administered) versus by the participant using a PCA pump (self-administered), and when monetary alternatives were presented in either ascending or descending sequence. The data show that rivastigmine (1.5 and 3 mg), as compared to placebo, did not significantly alter total choices for methamphetamine (p=0.150). Importantly, the number of infusion choices was greater when methamphetamine was available then when saline was available (p<0.0001), and the number of money choices was greater when saline was available then when methamphetamine was available (p<0.0001). The total number of choices for methamphetamine was not altered as a function of a participant's preferred route of methamphetamine use (p=0.57), and did not differ significantly whether they were experimenter-administered or self-administered (p=0.30). In addition, total choices for methamphetamine were similar made when money was available in an ascending versus descending sequence (p=0.49). The participants' years of methamphetamine use, recent use of methamphetamine (in the past 30 days), or baseline craving (indexed here as "Desire") on the day of the self-administration task were not predictive of number of choices for methamphetamine. In a subset of participants (N=8) for which data was available, individual dose of methamphetamine (3 x 3 mg, i.v.) produced significant increases in positive subjective effects, and a preliminary analysis revealed that 3 mg rivastigmine was associated with reductions in these responses, as compared to placebo. In summary, the current report indicates that there were no effects of rivastigmine on total choices for methamphetamine, that there were low levels of methamphetamine self-administration but these were 8 times greater than saline, and that choice behavior was insensitive to alternative reinforcers. In addition, we showed that rivastigmine may reduce the positive subjective effects produced by methamphetamine during self-administration.

PubMed Disclaimer

Figures

Figure 1

Average total methamphetamine (filled bars) or saline (open bars) infusions selected. Data represent the mean (±s.e.m.) of choices from a maximum possible of 10 made by participants on each of all self-administration days (days 12, 13, 14 and 15). Choices are plotted with regard to rivastigmine dosage group (0 mg, N=7; 1.5 mg, N=6; 3 mg, N=9).

Figure 2

Increases in subjective effects and monetary value produced by 3 mg doses of methamphetamine (N=8). Data represent change from baseline after the first, second, and third dose of methamphetamine (filled bars) as compared to a non-infusion choice (open bars) during the self-administration procedures. Data are mean ± s.e.m.

Figure 3

Increases in subjective effects and monetary value produced by 3 mg doses of methamphetamine as a function of rivastigmine dose (0 mg-open bars, N=4; 1.5 mg-hatched bars, N=1; 3 mg filled bars, N=3). Data represent change from baseline after the first, second, and third dose of methamphetamine only. Data are mean ± s.e.m.

References

1. Ahmed SH, Koob GF. Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology (Berl) 1999;146:303–312. - PubMed
1. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology. 2004;29:1470–1478. - PubMed
1. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17:947–963. - PubMed
1. Clemens KJ, Cornish JL, Hunt GE, McGregor IS. Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. Pharmacol Biochem Behav. 2006 - PubMed
1. Comer SD, Haney M, Foltin RW, Fischman MW. Amphetamine self-administration by humans: modulation by contingencies associated with task performance. Psychopharmacology (Berl) 1996;127:39–46. - PubMed

The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers - PubMed (original) (raw)